Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s stock price shot up 2.8% on Friday. The company traded as high as $11.50 and last traded at $11.30. 1,650 shares changed hands during trading, a decline of 65% from the average session volume of 4,762 shares. The stock had previously closed at $10.99.
Drugs Made in America Acquisition Stock Performance
The stock’s 50-day moving average is $10.89 and its two-hundred day moving average is $10.80.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with one or more operating businesses. Its Nasdaq-listed units trade under the symbol DMAAU.
The company does not have an established portfolio of drugs, medical products, or commercial services of its own. Its stated strategy is to pursue a merger, acquisition, or similar transaction with a company in the pharmaceutical, biotechnology, or related healthcare sectors, with an emphasis on businesses connected to drug development or manufacturing in the United States.
As a SPAC, Drugs Made in America Acquisition Corp.
Further Reading
- Five stocks we like better than Drugs Made in America Acquisition
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
